Pregnancy Risk Information Systems for Psychotropic Medications: A Practical Review for Clinical Decision-Making

Objective This review aimed to summarize pregnancy risk information systems for psychotropic medications and recent evidence on reproductive safety, with the goal of improving clinicians’ awareness of drug-specific risk information relevant to individualized clinical decision- making in women with psychiatric disorders of reproductive age.Methods We narratively reviewed official reproductive safety information resources from Australia, Europe, Korea, the United Kingdom, and the United States, together with recent umbrella-review evidence on psychotropic medication safety during pregnancy. Information on selected agents was organized by drug class.Results National systems differed in structure and clinical utility. Australia and Korea retain category-based elements, whereas sources from Europe, the United Kingdom, and the United States provide more descriptive, context-based information. Antipsychotics were mainly associated with neonatal extrapyramidal or withdrawal symptoms and metabolic risk signals for selected agents. Mood stabilizers and anticonvulsants were more strongly associated with congenital malformations and neurodevelopmental disorders. Benzodiazepines and hypnotics were mainly associated with neonatal sedation, respiratory depression, hypotonia, feeding difficulties, and withdrawal symptoms after late-pregnancy or labor exposure. Antidepressants were associated with neonatal adaptation symptoms, persistent pulmonary hypertension of the newborn, and postpartum hemorrhage. Recent umbrella-review evidence showed that most reported associations remained at suggestive or weak levels of evidence.Conclusion Psychotropic medication use during pregnancy should be guided by individualized risk–benefit assessment, integrating drug-specific safety signals, evidence quality, exposure timing, lactation and fertility considerations, and the risks of untreated psychiatric illness.